Hologic (HOLX) PT, Estimates Raised at Jefferies Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Hologic (HOLX) Buy Reiterated a Needham & Company Post Q2 on 'Encouraging' Return to Rev Growth
May 1, 2014 7:15 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and $26 price target on Hologic (NASDAQ: HOLX) following Q2 results which showed an 'encouraging' return to positive revenue growth.
Matson comments, "HOLX's F2Q14 results were well above consensus. Revenue upside was driven... More
Hologic, Inc. (HOLX) Tops Q2 EPS by 4c
April 30, 2014 4:02 PM EDTHologic, Inc. (NASDAQ: HOLX) reported Q2 EPS of $0.37, $0.04 better than the analyst estimate of $0.33. Revenue for the quarter came in at $625 million versus the consensus estimate of $609.35 million.
"Second quarter results reflect early progress towards our renewed focus on executional... More
